Saliva and Blood Biomarkers Move Closer to HPV-Associated Oral Cancer Detection
HPV-associated oral and oropharyngeal squamous cell carcinomas have climbed sharply over recent decades, yet no screening pathway exists for the dysplastic precursor lesions that often remain hidden from routine examination. A narrative review in the Journal of Clinical Medicine frames that gap as the central reason liquid biopsy has become so clinically attractive in this disease setting. When lesions arise in anatomically hard-to-visualize sites and early mucosal change is difficult to sample, a non-invasive molecular signal may offer the first practical route to detection.
The review centers on saliva and blood-based biomarkers as tools for early diagnosis, risk stratification, post-treatment surveillance, and recurrence monitoring in HPV-driven oral and oropharyngeal cancer. Rather than treating liquid biopsy as a single assay class, the article separates the biology of local shedding from the biology of systemic dissemination. That distinction is important because oral and oropharyngeal tumors do not behave identically in every compartment: saliva is positioned to capture locoregional tumor material, while plasma is more likely to reflect circulating disease burden and molecular residual disease beyond the primary site.
Why Saliva and Plasma Do Not Tell the Same Story
The most clinically useful message from the review is not simply that biomarkers exist, but that matrix choice changes what the assay can detect. Saliva appears best suited to picking up locoregional tumor signals, a biologically plausible finding in tumors arising directly within the oral cavity and oropharyngeal mucosa. Plasma, by contrast, is better aligned with systemic tumor signaling, including circulating tumor HPV DNA and other blood-borne analytes that may persist after treatment even when imaging remains unrevealing.
In practice, that means a single specimen type is unlikely to solve the entire problem. A saliva-first approach may be more sensitive to disease in the mucosal compartment, while blood testing may be better for residual disease and distant spread. Combined testing offers a stronger detection strategy than either matrix alone, particularly when the clinical question is not just whether cancer exists, but whether it is returning after therapy.
The review places circulating tumor DNA, viral nucleic acids, circulating tumor cells, and extracellular vesicles within this framework. Each biomarker reflects a different layer of tumor biology. ctDNA and viral nucleic acids can act as molecular traces of tumor shedding. CTCs suggest viable malignant cells entering circulation. Extracellular vesicles may carry nucleic acids and proteins that mirror tumor activity and intercellular communication. In HPV-associated disease, the viral component adds another analytical advantage: tumor-linked HPV material can serve as a recognizable marker of malignant burden.
The Surveillance Argument Is Strongest Where Imaging Falls Short
A one-sentence reality anchors the entire review: molecular recurrence may become visible before structural recurrence does.
That possibility gives liquid biopsy its strongest clinical appeal. The review identifies evidence supporting a clinically meaningful lead time before radiographic recurrence when dual-fluid testing is used to detect molecular residual disease. For oncologists managing patients after definitive therapy, earlier molecular warning could alter follow-up intensity, trigger closer examination of equivocal symptoms, and guide the timing of salvage intervention. In HPV-positive disease, where outcomes can be favorable but recurrence still demands prompt recognition, the difference between molecular and radiographic detection can shape subsequent care.
The article also emphasizes that saliva and plasma are not competing technologies so much as complementary ones. Their integration may improve sensitivity in the postoperative or post-radiation setting, when anatomy has changed and conventional exam findings may be difficult to interpret. A biomarker that tracks only one compartment risks missing disease biology unfolding elsewhere. By contrast, a dual-matrix strategy is more consistent with the heterogeneous way HPV-driven tumors shed material.
Standardization Remains the Bottleneck
The review is careful not to overstate readiness for routine use. Across the studies examined from 2015 through 2025, the literature still suffers from variability in assay methods, pre-analytic handling, and validation design. Sample collection, processing, storage, and analytic thresholds all influence whether a biomarker signal is reliable or misleading. In liquid biopsy, those details are not technical footnotes; they determine whether the result can be trusted at the bedside.
This is where the field still looks less like a finished diagnostic program and more like a set of promising but unevenly developed tools. The review calls for standardized pre-analytical protocols and robust prospective validation before saliva- and blood-based tests can be integrated into routine surveillance pathways. Without harmonized workflows, even biologically sound markers can produce inconsistent performance across centers.
The emphasis on standardization also reflects a broader lesson from oncology biomarker development. Assays that perform well in selected cohorts often lose precision when deployed in real-world practice, where specimen timing, treatment heterogeneity, and laboratory variation complicate interpretation. HPV-associated oral and oropharyngeal cancer will not be an exception to that rule.
A Dual-Fluid Model for Earlier Intervention
The clinical promise of this review lies in its practical vision: use saliva to capture what is happening locally, use plasma to capture what is happening systemically, and interpret the two together rather than in isolation. That approach could support risk-adapted surveillance, earlier intervention, and fewer unnecessary invasive procedures in patients who have already completed definitive treatment. It also fits the anatomy of the disease, where accessible screening remains difficult and precursor lesions often escape detection.
Still, the field has not yet crossed into established routine care. Prospective studies will need to prove which biomarker combinations are reproducible, which thresholds matter clinically, and which patients benefit most from intensified molecular monitoring. Until then, the strongest conclusion is constrained but meaningful: liquid biopsy is becoming a credible strategy for HPV-associated oral and oropharyngeal cancer, but its role will depend on validation, standardization, and careful integration into surveillance programs rather than on biomarker enthusiasm alone.